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Abstract 
In 1996, the state of California was the first in the union to allow for the use of medical 
marijuana. Since then, 28 more states have enacted similar laws (National Conference of State 
Legislatures, [NCSL], 2017). With the ever-growing opiate problem that has now been classified 
as an epidemic by the Centers for Disease Control and Prevention, medical marijuana could be a 
viable alternative to this this problem. As of 2014, the CDC reported opioid deaths were up 
369%, which is more than 91 deaths per day from overdose (Centers for Disease Control, [CDC], 
2017). The purpose of this study is to compare medical marijuana to opiates in safety and 
addiction; in addition, the efficacy of using cannabis as an alternative for individuals who deal 
with chronic pain will be investigated. A literature review was conducted to find systematic 
reviews, meta-analyses and randomized controlled trials (RCTs) that evaluated medical 
marijuana and opiates for the treatment of chronic pain. Four databases were surveyed with 
multiple sources found in CINAHL, Cochrane Database, PubMed and PsycINFO. Current 
literature shows that cannabinoids may provide potential benefit with short-term use, but not 
without possible adverse effects. With the current lack of research on long-term treatment of 
chronic pain with cannabinoids, additional research needs to be conducted to further understand 
the potential adverse effects associated with cannabinoid use. 
 Keywords: adverse effects, cannabinoid addiction, cannabinoids, chronic pain, efficacy, 
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Cannabinoid Therapy in Chronic Pain Management  
 Cannabis, cannabinoids and medical marijuana all encompass a topic that is highly 
controversial, as well as lacking in scientifically based evidence for chronic pain therapy. To 
date, the Food and Drug Administration (FDA) has approved three different cannabinoid based 
products that are currently being used for various medical issues, such as Dronabinol (Marinol 
and Syndros) and Nabilone (Cesamet). Limited amounts of research have been conducted due to 
the Drug Enforcement Administrations (DEA) schedule of cannabis as a Schedule I drug. The 
DEA classifies drugs based on four criteria. First, the DEA evaluates the potential for abuse 
followed by the safety of the drug, the potential for addiction and whether or not it has medical 
benefits for patients. Based on the scoring of each drug, the DEA classifies drugs into five 
categories, Schedule I being the most dangerous to Schedule V, which has the lowest potential 
for causing harm. The schedule associated with cannabis continues to limit research as well as its 
use, however, many states are reevaluating whether or not it should be illegal. Due to the recent 
legalization of medical cannabis in multiple states within the United States, it is important to 
better understand the mechanism of action of medical cannabis (MC), the adverse effects as well 
as benefits that can be provided through its use. Nugent et al. (2017) note, “Cannabis is 
increasingly available for treatment of chronic pain, yet its efficacy remains uncertain” (p. 327). 
Chronic pain is also a highly discussed topic due to the difficult nature of finding proper therapy 
to improve overall quality of life. Patients who deal with chronic pain are often left with 
prescription opiates for pain management, all of which have adverse effects. Authors Feingold, 
Goor-Aryeh, Bril, Delayahu, and Lev-Ran (2017) state, long-term treatment with opioids may be 
complicated due to tolerance and addiction, which may not be adequately managed and 
potentially worsen the pain. To better care for the ever-growing population of individuals dealing 
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with chronic pain, further exploration of cannabinoid therapy would be beneficial. Additional 
exploration of cannabinoid therapy as a possible alternative to opioid treatment could also prove 
to be of benefit.  
 This research project will explore whether cannabinoid therapy is as efficacious and safe 
as conventional therapy modalities when dealing with chronic pain management. With a better 
understanding of cannabinoids’ adverse effects and beneficial qualities, providers may be more 
apt to look at alternative therapies for patients who have shown no improvement in quality of 
life. The lack of data on the efficacy and safety of cannabinoids poses a barrier to physicians’ 
involvement, (Ware, Wang, Shapiro & Collet, 2015). An in-depth evaluation of the adverse 
reactions, addictive effects as well as clinical and statistical significance will be examined in 
those who choose to try cannabinoid products for chronic pain therapy. It is important to be 
involved and to comprehend all aspects of chronic pain and how to thoughtfully manage it in 
order to improve patient’s overall quality of life.  
Statement of the Problem  
 
 According to Boehnke, Litinas, and Clauw (2016), opiates are one of the most commonly 
used medications to treat chronic pain. With that notion, opiates are also ineffective for many 
types of pain as well as associated with addictive and significant morbidity and mortality rates. 
With the ever-growing opiate epidemic, an alternative treatment modality would be of great 
benefit. Cannabinoid therapy could be a potential secondary option rather than continued opiate 
therapy. Cannabinoid use for chronic pain management has been a topic of controversy within 
the United States for several years and remains so due to the legal restrictions. Regardless of the 
controversy, there may be benefits for those who deal with chronic pain and for those who seek 
to eliminate opiates as a treatment option. Because of the growing opioid problem within the 
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United States, it would be beneficial to begin to consider possible alternative therapies for 
management if research supports a drugs advocacy and safety. 
Research Questions  
 
 Is medical cannabis safe to use for chronic pain? What are the documented adverse 
effects associated with using this medication? 
 How addictive is medical cannabis compared to other addictive substances? What 
addictive qualities are associated with starting this medication? 
 What has been shown to be more effective in the treatment of chronic pain, medical 
cannabis or opiates? 
Methodology 
 The databases searched for this research topic include CINAHL, Cochrane Database, 
PubMed and PsycINFO from October 2017 through January 2018. ProQuest RefWorks was 
utilized for the organization and removal of duplicated articles. From the various search engines, 
a total of 21,697 articles were found. Keywords were used to narrow the research topic and 
include: adverse effects, cannabinoids, cannabis, chronic pain, drug therapy, efficacy, marijuana, 
medical cannabinoids, medical marijuana, meta-analysis, pain, pain management, quality of life, 
safety, systemic review, and tolerability. These keywords found articles that were added into a 
search builder. The builder allowed for a more extensive search throughout each database. To 
further narrow the search, advanced settings and limits of exclusion were used to select articles 
only relating to clinical trials, comparative study, meta-analysis, randomized controlled trials and 
systemic reviews. Further exclusion was based upon if the articles were not published in the 
English language, related to pain other than chronic or non-cancer pain and did not discuss the 
safety or efficacy of the therapy. Based on these results, 4,021 articles presented, a refined search 
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to just subject headings were used to further narrow the search. The subject headings used 
include: “Adverse Effects”[MH], “Cannabinoids”[Mesh], “Cannabinoid Therapy”[Mesh], 
“Cannabis”[Mesh], “Chronic Pain”[Mesh], “Marijuana Smoking”[Mesh], “Medical 
Marijuana”[Mesh], “Non-cancer pain”[Mesh], “Quality of life”[Mesh], “Pain” [Mesh], 
“Cannabis”[MH], “Chronic Pain”[MH], “Drug Therapy”[MH] and “Medical cannabis”[MH]. 
The subject headings allowed for the research topics to be combined or for topics to be searched 
alone by using “AND” and “OR” between each subject heading. From the use of the subject 
headings, the refined searches and exclusion criteria, the articles used within this Literature 
Review were evaluated and selected for this topic. 
Anticipated Results  
 
 A review of the available literature reveals that there are limited amounts of research 
relating to cannabinoid use for chronic non- cancer pain. Due to the limited amount of research, 
it is anticipated that the information will contain areas of bias and/or have restricted numbers of 
participants that in turn, will impact the way the research trials were conducted. The difficulty of 
conducting research on such a tightly monitored drug does not allow for much opportunity for 
long duration trials. It is anticipated that the research will be focused toward the three current 
FDA approved cannabinoid drugs: Marinol, Syndros and Casamet, rather than the large spectrum 
of cannabinoid classes present. With the information provided in the literature review, clinicians 
will be better informed on cannabinoid products, and how to approach cannabinoid therapy for 
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Review of Literature  
Cannabinoids for Chronic Pain- Safety and Adverse Events   
 
 In theme one, introduction of cannabinoids for chronic pain, seven studies were reviewed 
for evaluation of the safety and adverse events associated with cannabinoids. Five of the seven 
studies focused on common adverse events while three found central nervous system (CNS) ties 
with cannabinoid use. Only one study evaluated cannabinoid use over a long-term trial, the 
others were confined to shorter trial durations. Due to the short trial durations, each study 
suggested further research is warranted to better understand the safety outcomes associated with 
cannabinoid use.  
 Whiting et al. (2015) designed a meta-analysis and systematic review to determine the 
benefits and adverse events associated with cannabinoids compared to a placebo or no treatment. 
A total of 79 randomized controlled trials (6462 participants) from various countries with various 
placebos met the inclusion criteria. While many of the 79 studies suggested cannabinoids may 
improve symptoms, many of them did not reach statistical significance. Of the 79, only 28 
studies (2454 participants) assessed chronic pain. Within these studies, various types of 
cannabinoid products were evaluated such as nabiximols, smoked THC, nabilone, THC 
oromucosal spray, vaporized cannabis and capsules. Of these studies, only two were found to be 
of low bias risk, while nine were unclear and 17 were high risk. In eight of the 28 studies, 
patients who reported at least 30% decrease in pain were those who used cannabinoids rather 
than those who used a placebo (OR = 1.41; 95% CI =0.99-2.00). Data was also found relating 
adverse events to cannabinoids in 62 of the 79 studies. Common adverse events noted included 
dizziness, dry mouth, nausea, fatigue, hallucinations, drowsiness and confusion. Further research 
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showed that cannabinoids were associated with a greater risk of any kind of adverse event, 
serious adverse events, as well as, withdrawal (Whiting et al., 2015).  
 This study demonstrated that cannabinoids are likely to cause adverse events while being 
used for medical purposes. While participants noted a decrease in pain compared to the placebo 
in some trials, there was still a lack of statistical evidence for proof. One of the limitations of this 
study is that various cannabinoids products and dosage types were evaluated at once. It made it 
difficult to evaluate the results of benefits and adverse events due to the wide variety of products. 
To better understand the exact effects further analysis on a specific type of cannabinoid as well 
as dose would be more beneficial. Another thing to note would be this project was funded by the 
Swiss Federal Office of Public Health. It is unsure if there was any bias in selecting and 
conducting any of this research but would be beneficial to make note of.  
 Lynch and Campbell (2011) conducted a systematic review of randomized controlled 
trials (RCTs) examining cannabinoids in the treatment of chronic non-cancer pain. There was a 
total of 80 abstracts and only 18 of those (766 participants) met the inclusion criteria for further 
analysis. Of the 18, only 15 studies indicated there was a significant analgesic effect in 
cannabinoid users compared to that of the placebo groups. From the studies, no serious adverse 
effects were noted. Mild to moderate adverse effects were well tolerated overall, however, there 
were a few cases of participant withdrawal due to these effects. Dizziness, sedation, dry-mouth, 
nausea and concentration disturbances were among the most common adverse effects. Daily 
doses of nabilone 2 mg was compared to dihydrocodeine 240 mg and found the mean baseline 
pain was 69.6 mm on the 100 mm Visual Analogue Scale (VAS) had dropped to 59.93 mm for 
nabilone and 58.58 for dihydrocodeine. The scores decreased significantly compared to that of 
the placebo (Lynch & Campbell, 2011).  
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 Limitations to the findings in this study are the small sample sizes, modest effect sizes 
and short trial durations. It was also documented that cannabis may only decrease pain to a 
moderate degree and remains to be a substance that is further researched for long duration effects 
as well as safety and abuse potential. The authors have acknowledged these limitations and voice 
it is for patients to decide the effectiveness of the therapy as well as the need for further large 
scale, detailed research trials. 
 Campbell, Tramer, Carroll, Reynolds, Moore, and McQuay (2001) conducted a 
qualitative systematic review of randomized controlled trials (RCTs) to evaluate whether or not 
cannabis is an effective and safe alternative treatment option for pain management. The 
outcomes of the studies were evaluated based on pain relief scores, pain intensity and adverse 
effects. A total of 20 RCTs were identified and nine RCTs consisting 222 participants were used 
within this research. Four different cannabinoids, dosages ranging from 2-10 mg depending on 
the substance, were used within this trial and the comparators were oral codeine 50-120 mg and 
oral secobarbital 50 mg. Authors conducted various follow up periods due to the different 
cannabinoid types and the results were qualitatively summarized. Results showed THC users had 
a significantly lower breakthrough pain while on morphine compared to the control using just 
morphine (170 mg vs 410 mg per three weeks). In another group, 5 mg of THC was comparable 
to 50 mg of Codeine. However, all studies reported adverse effects and two participants 
withdrew due to the adverse effects. Authors found that 20 mg of THC was sedating in all 
participants, while 10 mg of THC was better tolerated than 60 mg or 120 mg of codeine, 
however, it still had a greater frequency of adverse effects such as numbness, dizziness, 
disconnected thought, slurred speech and muscle twitching. Results also revealed that 
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cannabinoids were no more effective than codeine and have psychotropic events as well as 
depressant effects on the central nervous system (CNS) (Campbell et al., 2001).  
 The authors do not go in depth discussing the limitations of the study which could call 
into question the validity of the results. One addressed limitation was similar to many of the 
studies reported prior, a very small study size. They note that only two of the 20 trials had more 
than 30 participants. Due to the small sample size it is difficult to get an accurate account of the 
overall findings when only applying the results to such a small population. This study was 
conducted in 2001 and further research has been conducted on safety and adverse events.  
 Martín-Sánchez, Furukawa, Taylor and Martin (2009) assessed the efficacy as well as 
harms of cannabis in the treatment of chronic pain. They designed a systematic review and meta-
analysis of double-blind randomized control trials that compared the placebo to any cannabis 
preparation for chronic pain subjects. The study included eighteen trials in which participants 
presented with constant or intermittent paint for a minimum of 6 months. The participants were 
required to have any form of cannabis preparation, which contained at minimum delta-9-
tetrahydrocannabinol (THC), other synthetic derivatives of THC were accepted. The control 
group received a placebo treatment. The trial used, “intensity of pain” numeric analogue scales 
for participants to rate their pain throughout the study. Harms were analyzed with Odds Ratios 
(ORs) and number needed to harm (NNH) by examining the number of adverse events 
experienced by each group participant. Results for the efficacy showed a standard mean 
deviation in favor of cannabis, a fixed effects model of -.61 (-.84 to -.037) with statistical 
homogeneity (I2 = 0.00%; p = 0.50). The analysis of harms was divided into perception, motor 
function and altered cognitive function. Harms related to altered perception (OR = 4.51; 95% CI 
= 3.05-6.66), p = .42, NNH: 7 (6-9); motor function alterations (OR = 3.93; CI = 2.83-5.47), p = 
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.68, NNH: 5 (4-6); and motor function changes (OR = 4.46; 95% CI = 2.37-8.37), p =.99, NNH: 
8 (6-12). The results of this review found that there was evidence supporting the efficacy of 
cannabis therapy for those with chronic pain. However, data supported there was a high number 
of serious adverse events in short-term trials, predominantly linked to central nervous system 
such as speech disorders, muscle twitching and numbness (Martín-Sánchez et al., 2009). 
 Due to cannabis’ antinociceptive effects, further evaluation and study is warranted to 
better understand the analgesic effects in patients with chronic pain. The authors remained 
unbiased and focused on a specific design that allowed for more accurate evaluation of the topic 
being researched. Due to the small sample size, the statistical significance is lost as well as the 
short duration period does not allow for comparison to real life and thus results may be less 
extreme. The study also used different dosage ranges by reference to the same placebo. This 
resulted in homogenous results decreasing the need for comparison by subgroups. Funding was 
provided by the Spain National Drug Plan which had no role in the study conduct, analysis or 
interpretation as noted by the authors.  
 Ware, Wang, Shapiro, and Collet (2015) conducted a multicenter cohort study over a 
year’s span with a standardized cannabis product, THC (12.5% Tetrahydrocannabinol), to better 
understand the safety of cannabis use for medical purposes. The study focused on three areas of 
evaluation: outcomes of serious adverse events and non-serious adverse events of cannabis 
treatment for chronic pain, to examine whether cannabis effected pulmonary and neurocognitive 
function and explore the effectiveness of improving pain intensity and quality of life. The study 
consisted of 431 adult participants from seven clinics within Canada who had chronic non-cancer 
pain for at least six months. 215 that were recruited to the cannabis group used a mean daily dose 
of 2.5 g/d of cannabis and 216 controls used no cannabis products. Of the 431 participants, 67 
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cannabis users and 34 from the control discontinued the study before the year’s end due to 
reasons not otherwise specified within the study. Results showed medical cannabis users were at 
increased risk of non-serious adverse events, 818, ranging from mild to moderate events such as: 
headache, nasopharyngitis, nausea, somnolence, and dizziness compared to the 581 events 
documented in the control (IRR = 1.64, 95% CI = 1.35-1.99). While the medical cannabis group 
had significantly higher non-serious adverse events, members reported improvements in tension-
anxiety, depression-dejection, anger-hostility, and fatigue-inertia compared to the control. 
Participants in the medical cannabis group had a significantly higher average pain intensity 
baseline compared to the control, however, more control participants used opioids, 
antidepressants and anticonvulsants compared to the former. Overall, individuals in the medical 
cannabis group experienced better pain control than the control (change = .92; 95% CI = .62-
1.23) vs (change = .18; 95% CI = -.13) (Ware et al., 2015).  
 The authors of this study note that this may be the only long-term study evaluating the 
safety of medical cannabis. Compared to the other studies used, this is the only one whose 
timeframe is longer than one year. The study did have several limitations that need to be 
addressed. The study had a relatively small sample size as well as a significant dropout rate. The 
dropout rate could be due to selection bias as noted by the authors or due to a lack of experience 
with the medication or the adverse events. Individuals within the medical cannabis group were 
experienced users which hinders results in that more adverse effects were noted with the naïve 
user compared to that of the experienced user. Lastly, because the study was not randomized or a 
blinded study, improvements in the efficacy could have been due to being in the study, 
regression to the mean or natural history of the disease.  
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 Nugent et al. (2017) conducted a systematic review of observational as well as 
interventional trials to determine if cannabis use in chronic pain adult populations has marked 
short and long-term physical and mental health effects. New clinical trials as well as cohort 
studies were searched and a total of 13 systematic reviews and 62 primary studies were evaluated 
for cannabinoid harm related events. From these results, 30 chronic pain trials were further 
evaluated for this study. The authors used the numerical rating scale (NRS) from 0 to 10 or 
participants who had clinically significant improvement of > 30% reduction, or approximately 2 
points on the NRS and 20 mm on the visual analogue scale. Results from this study conclude that 
there is not enough evidence to suggest that cannabis use has potential benefits and harms. The 
study does highlight that among the general population, there is small, short-term effects in 
cognition in active users but limited data for adverse mental health effects in the long term. 
There was also no detection of significant difference between the cannabis group compared to 
the control group when it came to serious adverse events (IRR = 1.08; 95% CI = 0.57-2.04). This 
study did evaluate long-term effects associated with cannabis use and found it to be associated 
with cannabinoid hyperemesis syndrome as well as incident cannabis use disorder (OR = 9.5; 
95% CI = 6.4-14.1), both of which the authors believe practitioners and patients should be aware 
of (Nugent et al., 2017).  
 The authors acknowledge the limitations within the study and begin mentioning many of 
the patient populations were selected rather than obtained through randomized control trials. The 
study also did not evaluate dispensaries and those who get therapy from them. Due to this, many 
of the studies assessment of cannabinoids is substantially lower than the products that can be 
obtained from a dispensary. Finally, there is relatively small number of participants from which 
strict data was obtained. Authors note it was impossible to assess the number per day of cannabis 
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smoked cigarettes for example. It has been suggested that any methodologically strong research 
conducted in cannabis research will likely add to the strength of the evidence found thus far. The 
U.S. Department of Veterans Affairs, Veterans health Administration, Office of Research and 
Development, Quality Enhancement Research Initiative all contributed financial support.    
 Issa, Narang, Jamison, Michna, Edwards, Penetar, and Wasan (2014) conducted a multi-
dose, randomized, double-blind, placebo-controlled, crossover trial of 30 chronic non-cancer 
adult patients using opiate therapy was conducted to identify if oral Dronabinol has psychoactive 
effects comparable to smoking marijuana. There were two groups evaluated for this study. The 
first group consisted of 30 individuals using Dronabinol, (10 mg and 20 mg capsules), with 
prescription opiates; only one of the 30 did not finish the trial due to inability to concentrate. The 
second group consisted of 20 individuals who were without pain and smoked a low and high 
dose of marijuana, (1.99% and 3.51% ∆9 THC). The Addiction Research Center Inventory 
(ARCI) was used to evaluate and compare dronabinol with smoked marijuana. Findings suggest 
that oral Dronabinol had similar psychoactive effects to that of smoked marijuana according to 
the ARCI. The ARCI highlighted that there was not much of a difference between the 10 mg and 
20 mg doses of Dronabinol; however, there was a consistent and significant difference when 
being compared to the placebo. It was noted that although dronabinol takes longer to reach the 
same peak as smoking marijuana (2 hours compared to 30 minutes), it does not necessarily have 
the same abuse liability as marijuana (Issa et al., 2014).  
 Similar to many of the studies reviewed thus far, the number of subjects was limited and 
the dronabinol group consisted of a heterogenous sample on various dosages of opiates. Due to 
the varied dosages, there is inconsistent comparisons between everyone. Another limitation to 
the study is that there was no comparison group to the control that used opiates. The authors 
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acknowledged that opiate therapy can cause similar psychoactive effects to smoking marijuana 
thus, questioning the validity of the results. The study also only used one primary measure, the 
ARCI, to compare oral dronabinol to smoked marijuana. With only one means of measurement, 
there is not sufficient or definitive data to conclude there is abuse potential for a drug. The 
authors make note that these laboratory findings may or may not translate across to the clinical 
realm where there could be an increased chance of dronabinol abuse, thus, further study is 
required on this topic. This study was supported by funding from the Solvay Pharmaceuticals 
Inc. grant as well as a grant from the national Institute on Drug Abuse.  
Comparison of Addictive Substances to Cannabinoids 
 In theme two, comparison of addictive substances to cannabinoids, three studies were 
reviewed. Of the three studies, each evaluated a different addictive substance such as opiates, 
alcohol and nicotine. The substances evaluated were then compared to other common addictive 
substances to evaluate the extent of addiction between each.  
 Feingold, Goor-Aryeh, Bril, Delayahu, and Lev-Ran (2017) conducted a cross-sectional 
study in Israel between two separate clinics and looked at 888 adults receiving treatment for 
chronic pain and whether or not these patients were more apt to abuse opioids and medical 
cannabis (MC). Various screening tools used to evaluate patients participating in the study such 
as the Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition (DSM-IV) Criteria, 
Portenoy’s Criteria (PC) as well as the Current Opioid Misuse Measure (COMM) questionnaire.  
Further screenings were done for depression, Patient Health Questionnaire (PHQ-9) as well as 
(GAD-7), generalized anxiety disorder scale to evaluate participants psychiatric comorbidities 
while using opiates and MC. Of the 888 participants, 471 were treated with prescription opiates, 
329 were treated with MC, 77 were treated with both opiates and MC and 5 did not use either 
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opiates or MC. The results of the study indicated that the participants who were treated with 
opiates had a greater prevalence of problematic use (52.6%) compared to MC participants 
(21.2%). The prevalence of problematic use between opiates and MC was documented in Figure 
I.  Three of the various screening tools were used within the study. Problematic use of opiates for 
the DSM-V, PC, and COMM are as follows (52.6%, 17.1%, and 28.7%). Problematic use of MC 
was documented with DSM-V and PC as follows (21.2% and 10.6%). COMM was not used for 
evaluating problematic use of MC because it solely deals with opiate misuse. Individuals with 
problematic use of opiates also consumed alcohol (32%), non-prescribed cannabis (19%), LSD 
(1.1%) and synthetic cannabinoids (0.7%). Likewise, individuals with problematic MC use 
consumed alcohol (36.9%), Ecstasy (1.1%), LSD (0.05%), Heroin (0.5%). Mental health 
Figure I.I 
 
Figure I. Prevalence of problematic use of prescription opioids and medical cannabis among pain patients, 
according to the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV), Portenoy’s 
Criteria (PC), and Current Opioid Misuse Measure (COMM).  
Adapted from Problematic use of prescription opioids and medical cannabis among patients suffering from chronic 
pain, by D. Feingold, I. Goor-Aryeh, S. Bril, Y. Delayahu, and S. Lev-Ran, 2017, American Academy of Pain 
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screenings also revealed opiate users were more likely to be diagnosed with depression than 
those using MC (Feingold et al., 2017).    
 The conclusion of the results reveal there is problematic use in both opiate as well as MC; 
the combination of the two are associated with patients who have a higher level of pain, alcohol 
use, depression and anxiety. The authors identified various downfalls in the study. First, the 
response rate from participants was low, possibly indicating the prevalence of problematic use 
could be much higher. The data also was obtained by self-report causing the results to be biased 
due a lack of information. There was also no complete diagnosis for psychiatric evaluation in 
those individuals who deal with problematic use, only screening instruments were used rather 
than a face to face follow up.  
 Darvishi, Farhadi, Haghtalab, and Poorolajal (2015) conducted a meta-analysis on the 
effects of alcohol use disorder (AUD) on suicidal thought and behavior. A total of 31 studies 
were included within the research, all of which were published in English. From the selected 
studies, there was a total of 420,732 participants. The authors used relative risk (RR) and odds 
ratios (OR) to determine the significance between the studies and participants due to both being 
used between various studies. “There was a significant association between AUD and suicidal 
ideation (OR = 1.86; 95% CI = 1.38 to 2.35), suicide attempt (OR = 3.13; 95% CI = 2.45 to 
3.81), and completed suicide (OR = 2.59; 95% CI = 1.95 to 3.23 and RR = 1.74; 95% CI = 1.26 
to 2.21)” (Darvishi et al, 2015, p. 1). The authors did detect two extreme values within the 
suicide attempt and completed suicide, these values were excluded from the analysis. Among the 
studies evaluated for AUD and suicidal ideation and attempt, considerable heterogeneity was 
documented (I2 = 76.8%, p < 0.001) and (I2 = 88.5%, p < 0.001). Based on the evidence 
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presented within this study, AUD can be considered a possible indicator of premature death as 
well as a predictor of suicide (Darvishi et al., 2015).  
 The study was financially supported by an Islamic Azad University which may or may 
not have had an impact on the research methods, interpretation and results. The authors did 
acknowledge that there may be overestimation of the results due to fully adjusted forms of 
relative risk (RR) and odds ratio (OR) when not all studies did the same. Secondly, 12 studies 
were excluded due to the fact the full text was not available which may contribute to selection 
bias. There were also discrepancies across studies that need to be taken into consideration. The 
OR estimates for suicidal ideation ranged between 0.5 to 3.10, while suicide attempt ranged from 
1.5 to 10.50 respectively. 
 Richter, Pugh, Smith, and Ball (2016) conducted a quantitative, peer reviewed study to 
assess the extent to which nicotine use occurs with other substances among young adults. 
Authors also sought to determine other variables such as demographics and implications of 
research and prevention. Participants were young adults that were gathered from two data sets, 
the first from the National Survey on Drug Use and Health (NSDUH) followed by Monitoring 
the Future (MTF). Participants were aged 12 and older (n = 55,271) in the NSDUH study and 
students in the 8th, 10th and 12th grades (n = 41,551). Authors examined alcohol, marijuana as 
well as other illicit drugs and prescription drugs as possible correlates to nicotine product use. 
The NSDUH data showed that 10.2% of participants used cigarettes only while 4.1% used other 
nicotine products. Those who used any type of nicotine product were qualified as being 
dependent upon nicotine. Of the respondents who used any nicotine product, a significant 
amount of data showed a higher prevalence to other substances such as alcohol, marijuana, poly-
substance use as well as substance-use disorders. MFT results had similar findings to that of the 
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NSDUH study, those who reported nicotine use of any kind had a higher prevalence of alcohol 
and other drug use. In the 12th graders studied that reported any form of nicotine use, co-
occurring use with other substances was documented (79.4% alcohol (OR = 11.5; 95% CI = 8.4- 
15.7), 59.7% marijuana (OR = 12.7%; 95% CI = 9.5- 16.8), 53.9% poly-substance use (OR = 
15.5; 95% CI = 11.4- 21.0), 18.8% prescription drugs (OR = 8.3; 95% CI = 5.4- 12.8), 8.5% 
other illicit drugs (OR = 19.1; 95% CI = 9.0- 40.6) (Richter et al., 2016).  
 The results of this study reveal that individuals who become dependent upon any form of 
nicotine product are of greater likelihood to use other types of substances. Authors 
acknowledged the two data sets did pose limitations to the study in that they were self-reported 
estimates which yield less accurate results. The study was also cross-sectional, therefore any 
association made within the studies was correlated. Lastly, the MTF did not inquire the same 
questions throughout the study which presents as large amounts of missing data. With these 
limitations, the results should be noted with slight caution. 
Medical Cannabinoids vs Opiate Efficacy 
 
 In theme three, medical cannabinoids vs opiate efficacy, five studies were reviewed for 
statistical and clinical significance. Statistical significance was highlighted in three studies while 
clinical significance was documented in two of the six. Statistically significant studies 
documented improvements in pain, quality of life as well as other areas. Clinically significant 
studies may not have shown statistical support of cannabinoid benefit, but per individual report, 
improvements were documented. The results reveal both pros and cons to medical cannabinoid 
use, thus further research is necessary to further understand the effects of this therapy.  
 Goldenberg, Reid, IsHak, and Danovitch (2017) conducted a systematic review and meta-
analysis to better understand three different questions. First, they wanted to determine whether 
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different forms of cannabis impacted health-related quality of life (HRQoL) conditions 
differently and if the condition/disease was associated with HRQoL. The authors also wanted to 
evaluate if the study design impacted the results of cannabis and cannabinoid use and HRQoL. A 
total of 20 studies were evaluated, 11 were randomized controlled trials (2322 participants) and 9 
were of cohort and cross-sectional study designs. Of the 20 studies, only 11 were used for 
evaluation of the meta-analysis due to measures of variability and means found within each 
study. The studies were divided into two groups based on cannabis type; six studies evaluated 
cannabis and 14 studied cannabinoids. Results of cannabis use for increased HRQoL were vague 
and most effects were non-significant or nearing zero. Some reports showed a mild benefit in 
some pain conditions while in others there was a decrease in HRQoL. The authors found that 
cannabis for physical HRQoL did show symptomatic relief but results were unclear if there was 
statistical significance. The cannabinoid group utilized five variations to assess HRQoL. Each 
cannabinoid analyzed resulted in different outcomes ranging from being of benefit to no 
significant documentation. When comparing cannabis and cannabinoids to a control group, no 
significant effects were documented (CI = -0.34 to 0.44) with physical and mental HRQoL. 
Although many studies did not report significant effects on HRQoL globally, some 
improvements were noted such as headaches and sleep disturbances (Goldenberg et al., 2017). 
 This study demonstrated how HRQoL can be impacted by either cannabinoids or 
cannabis. However, a major limitation was the HRQoL was often used as a secondary outcome 
because there was not a uniform quality of life measurement. Trends being evaluated could shift 
one direction or the other. Another area that is important to note is cannabis and cannabinoid use 
over different times and different diseases can impact the HRQoL. The study focuses on diseases 
other than pain in the assessment of the therapy outcome.  
CANNABINOID THERAPY IN CHRONIC PAIN MANAGEMENT  25 
 Narang, Gibson, Wasan, Ross, Michna, Nedeljkovic, and Jamison (2008) investigated the 
analgesic effects of cannabinoids among adult patients who reported moderate to severe non-
cancer pain, at least a 4 on the 0 to 10 numeric rating scale, and who were already using opiate 
therapy for greater than six months. The research design consisted of two phases. The first began 
as a randomized, single-dose, double-blinded, placebo-controlled, crossover trial in which 
participants were randomly given a 10 mg or 20 mg dose of Dronabinol or a placebo. The second 
phase of evaluation was an extension of the first phase, Dronabinol was used as an adjuvant 
therapy to their opiate therapy in an open-label titrated trial. One hundred sixty (n =160) 
individuals were screened and 30 individuals met the final criteria to begin the study. The results 
of this study concluded that individuals who used Dronabinol in Phase I found significant pain 
relief after 8 hours per the total pain relief at 8 hours score (TOTPAR), (20 mg vs placebo at p < 
.01, 10 mg vs placebo at p < .05). For adjuvant therapy in Phase II, dronabinol proved to have a 
significant effect in lowering pain from baseline (p < .001), decreasing pain bothersomeness as 
well as increased satisfaction in their therapy (p < .01). The use of Dronabinol proved to provide 
additional analgesia to patients with chronic pain, however, two prominent side effects were 
documented with the 20 mg dose. Both events related to heightened anxiety that lasted through 
the treatment day. Similarly, less prominent events were noted such as drowsiness, abnormal 
thinking, anxiety, eye irritation and anxiety (p < .05) (Narang et al., 2008).  
 These results suggest that cannabinoid therapy is effective for chronic pain management 
and pain relief. The analysis does suffer due to the small trial size, heterogeneous patient 
population, no control for Phase II, the length in which the trial for each phase was conducted, as 
well as a number of patients reported they were not naïve to cannabinoid use. The authors of this 
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study recognize the limitations as well as drawbacks of the study and recommended further 
research is warranted to evaluate the efficacy of cannabinoids for adjuvant therapy.  
 Boehnke, Litinas, and Clauw (2016) conducted a cross-sectional survey in Michigan, 
evaluating the efficacy of medical cannabis compared to opiates in chronic pain patients. A total 
of 374 participants who were 18 years of age or order voluntarily joined the survey. Authors 
used a 2011 Fibromyalgia Survey Criteria (FM score) which ranges from 0 to 31, with 31 
representing the most severe pain. The authors used this scale as it correlated with the initial 
hypothesis that chronic pain is more centralized rather than nociceptive. A 46-question survey 
was also used to evaluate participants type of pain and reason for medical cannabis use. Of the 
374 participants, 244 used cannabis to treat chronic pain (CP) and only 185 completed 
questionnaires qualifying their data for analysis. Of those with incomplete surveys, the results 
were not statistically significant. Results of the survey showed individuals with the highest FM 
score had the least drastic reduction in opiate use (-48%) which was significantly different from 
the lowest FM score (-79%; p = .03). Additionally, respondents reported a significant decrease in 
the number of medications used before and after cannabis use (2.38 vs. 1.81; p < 0.001). Lastly, 
medication side effects decreased significantly after the use of cannabis (6.51 vs 2.79; p < 
0.001). The authors combined the results from medication side effects and opiate reduction 
(r=.37, p = .0002) and found there are potential health benefits to using cannabis as a 
replacement therapy for opiates (Boehnke et al., 2016).  
 The authors of this article make special note towards the limitations of this study and the 
potential biases that could have caused skewed results. Using the questionnaire could contribute 
to unreliable recall data in that individuals could indicate whatever they saw fit. Another 
limitation included participants who had been using cannabis for longer periods of time; creating 
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a skewed questionnaire because there was no baseline questionnaire completed prior to the long-
term management. The authors continue to discuss the lack of representatives for a general 
population. The participants that were used were recruited from a medical cannabis dispensary 
providing a narrow population set. The authors offered suggestions for future study to better 
improve research results such as performing a longitudinal study design that recruits naïve 
participants to cannabis as well a preliminary baseline pain levels prior to starting therapy. 
 Aviram and Samuelly-Leichtag (2017) performed a meta-analysis with randomized 
controlled trials (RCTs) on cannabis-based medicines (CBMs). The goal was to gain knowledge 
on the efficacy and adverse effects (AEs) of CBMs for chronic pain treatment and postoperative 
pain treatment. The study compared analgesic effects of CBMs to a placebo. The RCTs consisted 
of 43 groups initially (2,437 adult patients), while only 24 (1,334 patients) were used for meta-
analysis due to eligibility. Pain reduction was noted in limited amounts in chronic non-cancer 
pain, -0.39 (-0.49 to -0.29; p < 0.0001). Results of the baseline pain intensity change indicate a 
fixed-effect model result of -0.35 (-.43 to -.27; p < 0.0001) and a random-effect model showing -
0.40 (-0.58 to -.21; p < 0.0001), both of which are in favor of CBM over the placebo. In some 
RCTs, there was a clinically significant improvement of a 2 point or more decrease in pain (30% 
or 50% or more); however, the majority of studies did not show similar effects. The results of the 
meta-analysis concluded that while pain relief was noted, there was not statistically proven 
evidence between the studies. Furthermore, over half of the trials that were evaluated reported 
adverse effects (AEs) experienced by the patients. The most common AEs include central 
nervous system (CNS) and gastrointestinal system issues (Aviram & Samuelly-Leichtag, 2017).  
 One of the main limitations acknowledged by the authors was that not all of the studies 
used within this review met the criteria of the meta-analysis. The fact these studies were used 
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could have altered the result of the overall study effect. The studies that were evaluated were also 
almost entirely heterogeneous which could have affected the studies that had short washout 
periods. The authors discuss that many of the findings did not address the most common method 
in which cannabis is used, i.e, inhalation as well as whether prior cannabis consumption took 
place.  The study did not address the use of other medications that could also interact with CBMs 
and the outcomes that were documented.  
 Deshpande, Mailis-Gagnon, Zoheiry, and Lakha (2015) sought to determine if medical 
marijuana provides adequate pain relief to patients with chronic non-cancer pain (CNCP) as well 
as determine the therapeutic doses, adverse effects and specific indications related to medical 
marijuana use. The authors created a systematic review that was conducted on a group of six 
randomized control trials involving 226 adults (mean age of 45 to 50 years) in Canada. Of the 6 
RCTs, only 5 assessed medical marijuana use and were utilized within the study. Trial duration 
was short and ranged from 17 days to eight weeks. Authors used the visual analogue scale (VAS) 
to measure pain in participants. Results reported a statistically significant change in pain 
reduction with non-serious side effects in the medical cannabis group. The VAS noted a 0.7 
average daily difference between that of the placebo (score of 6.1) and medical cannabis group 
(score of 5.4). Clinically relevant pain reduction was also noted in three studies in which 
participants were using medical marijuana (46%, 52%, and 61%) compared to the placebo (18%, 
24%, and 26%). The participants documented a 2-point decrease in the numerical pain rating 
scale, which is equivalent to a 30% improvement in pain. While no serious adverse events were 
documented, medical cannabis was shown to have a greater incidence of adverse events 
compared to the placebo. One study being evaluated noted a statistically significant (p < 0.001) 
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increase in disorientation, sedation, confusion and dizziness in the cannabis group (Deshpande et 
al., 2015).  
 The study concluded while medical marijuana was associated with a reduction in CNCP, 
there were multiple short-term cognitive adverse effects associated with it. The study was 
heterogeneous in origin and could not report on the efficacy of cannabis because of this as well 
as due to the outcome variables. The authors state the cognitive effects documented with medical 
marijuana are also experienced in opioids and thus the same precautions should be enacted with 
either drug. Another limitation noted was the amount of medical marijuana participants were 
exposed to was much lower than what is available on the market. Due to the unknown nature and 
effects medical marijuana poses to individuals, further research was recommended by the authors 
of this study as well as incorporating standard measures on quality of life that go beyond pain.  
Discussion 
 
 The therapeutic properties of cannabinoids are showing promise through low addiction 
likelihoods and less severe health outcomes compared to other substances used on the market 
and throughout the world. The National Institutes of Health (NIH) has supported around 281 
projects totaling over $111 million on cannabinoid research. To date, research in the past has 
been lacking, but due to the potential of cannabinoids for alternative therapy, this area is 
continuously growing. Within this investment, 49 projects ($21 million) examined therapeutic 
properties of cannabinoids, and 15 projects ($9 million) focused on cannabidiol (CBD). Like 
other substances, adverse events (AEs) have been documented ranging from mild to severe 
which should be addressed prior to beginning therapy. Dry mouth, nausea and dizziness are 
among the mild AEs, while impaired cognition and CNS depression were documented as severe 
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AEs. Current evidence reveals cannabinoid therapy eliminates and/or decreases pain, improves 
sleep function as well as decreases the need for further medication. 
Is medical cannabis safe to use for chronic pain? What are the documented adverse effects 
associated with using this medication? 
 Cannabinoids have been around for many centuries and to date, it has begun to take a 
different face. Medical cannabis and cannabinoids are becoming more popular for various 
medical conditions, most notably, chronic pain. In the United States, medical cannabis can either 
be man-made or synthesized from the marijuana plant. Dronabinol currently is the only medical 
prescription (Rx) used within retail pharmacy; further cannabinoid substances are obtained at 
dispensaries. Due to the ever-changing role of cannabinoids, there is concern on whether it is 
safe for patient use. 
 A study conducted by Narang et al. (2008) mentions patients who used dronabinol 
reported significant pain relief, reduced pain bothersomeness and increased satisfaction 
compared with the baseline. The results of this study further concluded that when dronabinol was 
used in conjunction with opiates, additional analgesic relief was noted.  
 Further assessment of cannabinoid safety was conducted by Ware et al. (2015). The study 
assessed the safety of medical cannabis and found there was no change in overall organ system 
function. Neurocognitive testing revealed there was no difference in function after one year of 
medical cannabinoid use. There was no significant change in pulmonary function tests, however, 
residual volume was slightly decreased. The decrease in residual volume was most likely due to 
the smoked cannabinoids or other predisposing conditions prior to cannabinoid use. Blood 
testing also showed no change in liver, renal or endocrine function compared to the baseline one 
year prior. The results of long term cannabinoid effects as well as trials evaluating the effects on 
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the body are in the minority. Furthermore, additional studies are warranted in order further 
document whether other medical cannabis is safe for long term treatment of chronic pain.  
 Medical cannabis and cannabinoids have been associated with many adverse events 
(AEs) similar to those of common medications. Some of the most common AEs associated with 
medical cannabis and cannabinoid products include dizziness, dry mouth, nausea, fatigue, 
somnolence, euphoria, vomiting, drowsiness, confusion and hallucination (Whiting et al. 2015). 
Whiting et al. noted the data relating to the various AEs did not show any evidence relating to 
the type of cannabinoid used, rather the amount of cannabinoid was associated with greater 
likelihood of AEs. Dose of cannabinoids leads to a greater likelihood of experiencing AEs. In 
contrast to the previous study, Ware et al. (2015) found that increasing the daily dose of 
cannabinoid did not lead to increased serious adverse events or adverse events (IRR = 1.08, 95% 
CI = .57-2.04). While at the other end of the spectrum, a study conducted by Martín-Sánchez et 
al., (2009) concluded cannabinoid compounds pose more risk than benefit, and can possibly 
cause secondary problems for the patient. 
 Lynch and Campbell (2011) found the following relating to sedation, dizziness, dry 
mouth, nausea and concentration disturbances: 
  Adverse effects were generally described as well tolerated, transient or mild to  
  moderate and not leading to withdrawal from the study. This is a significant  
  difference from the withdrawal rates seen in studies of other analgesics such as  
  opiates where the rates of abandoning treatment are in the range of 33%. (p. 741) 
The percentages of patients who withdrew from the studies stated it was due to inadequate pain 
relief and/or the adverse side effects. Similarly, Narang et al. (2008) documents that despite the 
side effects of dronabinol in 10 mg or 20 mg doses, there was a significant difference in patient 
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satisfaction compared to the placebo (p < 0.01). There was no difference between the 10 mg and 
20 mg doses in terms of pain relief. Campbell et al. (2001) analyzed whether single doses of 
cannabinoids, specifically delta-9-tetrahydrocannabinol (THC) 5-20 mg, would be useful for 
breakthrough pain in acute or chronic settings. Results revealed it was no more effective than 
Codeine 50-120 mg when controlling pain. The results from this study documented the 10 mg of 
THC being more depressive on the CNS than 60-120 mg of codeine. Of note, common dosages 
of codeine range between 30-60 mg for pain management. 
 Mental health changes have been of great concern with the use of medical cannabis, most 
commonly CNS depressive effects. Like many other types of medications, medical cannabis has 
been documented to have serious AEs. Nugent et al. (2017) state cannabis has potentially serious 
adverse effects on mental health as well as cognition, but there is limited data to suggest the 
magnitude of risk or who is at greater risk. A study conducted by Issa et al. (2014), found 
dronabinol had significantly greater addiction research center inventory (ARCI) subscales 
compared to the placebo. This means dronabinol had similar psychoactive effects when 
compared to smoking marijuana. The psychoactive effects took longer to take effect with 
dronabinol compared to recreational marijuana (2 hours with oral dronabinol compared to 30 
minutes with smoked marijuana). The authors of this study stated that dronabinol does not 
necessarily have the same abuse liability as marijuana, but it should be taken into consideration 
as a potential risk for those using it for pain relief.  
 Little evidence has been found on long term use of medical cannabis, but according to 
Nugent et al. (2017), long term cannabis use was associated with cannabinoid hyperemesis 
syndrome (CHS). Patients experience severe cyclic vomiting, which can be alleviated by 
stopping cannabis products or taking hot showers. Little is known about CHS to date and further 
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research is warranted. If the cyclic vomiting continues, individuals are at risk for dehydration, 
electrolyte imbalances and other potentially severe conditions.   
How addictive is medical cannabis compared to other addictive substances? What 
addictive qualities are associated with starting this medication? 
 According to the CDC (2017), 1 in 10 marijuana users will become addicted compared to 
as many as 1 in 4 patients using opiates becoming addicted. Over 1 million individuals a year 
will become addicted to nicotine. Some of the most commonly abused drugs today include 
alcohol, cocaine, heroin, LSD, marijuana, prescription opioids, prescription sedatives, 
tranquilizers, prescription stimulants, and tobacco (National Institutes of Health [NIH], 2017). 
These substances also can have severe withdrawal symptoms associated with them. Opiates, 
prescription sedatives and tranquilizers, as well as steroids, were at the top of the list for the most 
withdrawal symptoms, and it was suggested medical attention be sought if withdrawal symptoms 
begin to occur. Lüscher (2018) wrote, withdrawal symptoms of cannabinoids are mild and short 
lived. In relation to other substances, it appears that withdrawal symptoms may be more tolerable 
with cannabinoids than other substances. When comparing medical cannabis to other addictive 
substances used around the world, cannabinoids rank relatively low in addiction rates compared 
to other commonly used substances. Lüscher highlights many of these differences in Table 1. An 
important aspect of the table that needs addressing is that the authors did not fully document the 
relative risk ratio on the far-right column. The ratio is more accurate when decimals are used, but 
in this graph the RR does not use decimals to document the result. Opioids, nicotine and alcohol 
all rank higher than cannabinoids in terms of the relative risk (RR) of addiction. The greater the 
number associated with relative risk, the greater the chance of addiction. Likewise, morphine, 
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heroin, codeine and oxycodone all induce strong tolerance and dependence which can lead to 
addiction.  
Table 1 
The mechanistic classification of drugs of abuse 
 
 
Name Main Molecular 
Target 




Drugs That Activate G 
Protein-Coupled 
Receptors 
    
Opioids µ-OR (Gio) Agonist Disinhibition 4 
Cannabinoids CB1R(Gio) Agonist Disinhibition 2 
γ- Hydroxybutyric acid 
(GHB) 
GABABR(Gio) Weak Agonist Disinhibition ? 
LSD, mescaline, 
psilocybin 
5-HT2AR(Gq) Partial Agonist ⸻ 1 
Drugs That Bind to 
Inotropic Receptors and 
Ion Channels  
    
Nicotine  nAChR(α4b2) Agonist Excitation 4 






Benzodiazepines  GABAAR Positive 
Modulator 
Disinhibition 3 
Phencyclidine, ketamine NMDAR Antagonist  ⸻ 1 
Drugs That Bind to 
Transporters of Biogenic 
Amines 
    
Cocaine DAT, SERT, NET Inhibitor  Blocks DA uptake 5 
















Note. From Basic and Clinical Pharmacology, 14e, by B.G. Katzung (Ed.), 2014, New York, NY: McGraw-Hill. Copyright 
2015 by McGraw-Hill Education.  
a5-HTxR, serotonin receptor; CB1Rm cannabinoid-1 receptor; DAT, dopamine transporter; GABA, γ-aminobutyric acid; 
Kir3 channels, G protein-coupled inwardly rectifying potassium channels; LAD, lysergic acid diethylamide; µ-OR, µ-
opioid receptor; nAChR, nicotine acetylcholine receptor; NET, norepinephrine transporter NMDAR, N-methyl-D-aspartate 
receptor; R, receptor; SERT, serotonin transporter; VMAT, vesicular monoamine transporter; ?, indicates data not 
available. 
bDrugs fall into one of three categories, targeting either G protein-coupled receptors, ionotropic receptors or ion channels, 
or biogenic amine transporters. 
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 Another very common and easily accessible substance is alcohol. Addiction to alcohol is 
not very common, but for those who do become addicted it becomes a serious health issue. 
Alcohol dependence and abuse has been linked with many health-related problems and diseases, 
one of which is the most well-known, liver damage. Individuals who become addicted to alcohol 
can experience very severe withdrawal symptoms rivaling opiates. Withdrawal symptoms such 
as tremor, agitation and anxiety become apparent 6-12 hours after cessation and symptoms can 
be severe (Lüscher, 2018). Alcohol is also associated with higher rates of suicide. This 
correlation can also be seen with the opiate epidemic due to overdosing on the medications.  
Darvishi et al. (2015) found significant association between alcohol and suicidal ideation (OR = 
1.86; 95% CI = 1.38, 2.35), suicide attempt (OR = 3.13; 95% CI = 2.45, 3.81); and completed 
suicide (OR = 2.59; 95% CI = 1.95, 3.23 and 95% CI = 1.26, 2.21) within their study. Unlike 
other forms of addictive substances, alcohol works on many different receptors in the brain as 
well as the cellular function. Opiates, cannabinoids and tobacco chiefly rely on specific receptors 
in the brain rather than many, like alcohol. Due to the various receptors in which alcohol works 
upon, it may explain why alcohol is ranked so highly among these other addictive substances. 
 Feingold et al. (2017) concluded that problematic use of opiates was more prevalent than 
problematic use of medical cannabis. After prolonged abstinence of opiate use, recovery in 
cognition is possible, however, it may take some time. Individuals who deal with chronic opiate 
abuse are less likely to have full recovery in cognition. Various neuroimaging techniques have 
been developed to evaluate opiate use on brain function. Significant differences in cognitive and 
motor impulsivity have been documented with chronic opiate use.  
 One of the most commonly known and used substances around the world is tobacco and 
nicotine. These elements surpass all other forms of known addictive substances and it has been 
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documented that more than 50 % of the adult population in some countries around the world are 
affected (Lüscher, 2018). The use of these products causes many associated diseases, many of 
which are reversible and preventable. Premature deaths are a leading factor associated with 
tobacco use. The CDC reports that around 400,000 adults die from nicotine related diseases each 
year. The number of deaths due to opiates continues to rise, and is becoming a potential rival to 
the documented nicotine related deaths (CDC, 2017). Due to so many health-related risks, many 
areas have banned smoking in public to prevent second hand smoke exposure, as well as a 
triggered relapse in those who have quit. Hatsukami, Stead, and Gupta (2008) state, “The portion 
who can achieve abstinence for at least 1 week is 25-51% and at least 3 months is 10-20%. By 6 
months, only 3-5% have achieved longstanding abstinence” (p. 2035). Richter et al. (2016) have 
shown that early use of nicotine products leads to a higher likelihood of starting other abusive 
substances such as opiates, marijuana and alcohol to name a few. Although tobacco and nicotine 
withdrawal is mild compared to opiates, and may resemble cannabinoids, those who succeed 
with cessation have a very high likelihood of relapse.  
What has been shown to be more effective in the treatment of chronic pain, medical  
cannabis or opiates?  
 In a study conducted by Ware et al. (2015), a visual analogue scale (VAS) was used to 
assess the perception of pain in patients. There was a reported difference in the VAS score 
between the placebo and the cannabinoid group. The results of the placebo score were 6.1 while 
the cannabinoid group was 5.4 respectively. Goldenberg et al. (2017) summarize findings 
pertaining to cannabinoids and cannabis in relation to health-related quality of life (HRQoL) and 
pain. The goal of measuring HRQoL is to assess physical, mental, emotional and social 
functioning of patient health. The findings suggest that the correlation between cannabinoids and 
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HRQoL are weakly positive in the seven diseases being researched (pain, multiple sclerosis, 
amyotrophic lateral sclerosis, traumatic brain injury, cancer related anorexia- cachexia 
syndrome, inflammatory bowel disease and human immunodeficiency virus). Some of the 
patients using cannabinoids for more common conditions, such as chronic pain, multiple 
sclerosis and inflammatory bowel disorder reported slight improvement in HRQoL, but not a 
statistically significant value. The conclusion of the findings revealed there is no significant 
effect on HRQoL, but for pain related diseases, this could be separate from the trend found in 
this study. The difficulty in determining whether the overall HRQoL was impacted in a positive 
way depends on each study design as well as duration.  
 There is an idea, that medical cannabis and cannabinoid products could aid in the current 
opiate epidemic as well as decrease the pain individuals endure. Boehnke et al. (2016) found that 
those who used cannabis for pain found not only improvement in pain symptoms, but a reduction 
in their current medications. According to Boehnke et al., Table 2 demonstrates many 
individuals reported a decrease in their mean number of medications (2.38 vs 1.81, respectively, 
p < .001), most notably opiates, nonsteroidal anti-inflammatory and antidepressants. Not only 
was there documented reduction in opiate use, but a decrease in medication side effects (r = .37, 
p = .0002), indicating there is potential health benefits to replacing opiates with cannabis. The 
results of this study are focused on areas in which dispensaries are accessible to patients, thus 
there are areas that were not surveyed that could have further impacted the results. 
 When surveying patient populations with chronic pain, Feingold et al. (2017) 
documented there was a greater prevalence of problematic use in opiate users compared to 
medical cannabis users. The study measured three different variables to aid in determining the 
overall prevalence of problematic prescription use. The first variable of study was the Diagnostic 
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and Statistical Manual of mental Disorders- Fourth Edition (DSM-IV). The DSM-IV is a manual 
used to help diagnose mental health disorders. Portenoy’s Criteria (PC) was the second variable 
and is a 10-item self-reported questionnaire that focuses on two main areas; first, having an 
intense desire for a drug and second, having a strong concern over the drugs availability. Patients 
also need to have one more positive finding, such as unsanctioned dose escalation for there to be 
documented problematic use. Current Opioid Misuse Measure (COMM) was the final test. It is a 
17-item self-reported questionnaire where all items are rated from “0 = never to 4 = very often.”  
According to Feingold et al., Figure I located on p. 20, demonstrated there is a significant 
difference in problematic use between opiate use and medical cannabis. The results are as 
Table 2  
Medication classes used before and after initiation of cannabis among the 
study population  
 
MEDICATION TYPE USE BEFORE INITIATION 
OFCANNABIS, N/N (%) 
USE AFTER INITIATION 
OFCANNABIS, N/N (%) 
Opioids 119/184 (65) 33/184 (18) 
Nonsteroidal anti-
inflammatory drugs 
115/184 (62) 38/184 (21) 
Disease-modifying 
antirheumatic drugs 
15/184 (8) 3/184 (2) 
Antidepressants 72/184 (39) 25/184 (14) 
Serotonin–norepinephrine 
reuptake inhibitors 
13/184 (7) 3/184 (2) 
Selective serotonin 
reuptake inhibitors 
34/184 (18) 8/184 (4) 
Other 69/184 (38) 40/184 (22) 
 
Note. From Medical cannabis use is associated with decreased opiate medication use in a 
retrospective cross-sectional survey of patients with chronic pain, by K. Boehnke, E. Litinas, D. 
Clauw, 2016, The Journal of Pain, 17(6), p. 739-744. Copyright 2016 by the American Pain Society.  
aStudy participants reported using fewer medication classes of all categories after inhalation of 
cannabis use.  
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follows, 52.6 %, 17.1%, and 28.7% for the DSM-IV, PC, and COMM in patients with opiate 
treatment (with or without medical cannabis use) and 21.2%, 10.6% for DSM-IV and PC for 
medical cannabis treatment (with or without opiate use). The conclusion of this study showed 
that individuals with problematic opiate use reported a higher average (p < 0.01) and maximum 
(p < 0.05) level of pain than those without. Individuals associated with problematic use were 
those who had used medical cannabis for greater than five years or more (p < 0.05). Individuals 
who used opiates compared to those who used cannabinoids were all documented of having a 
greater association with depression and anxiety, 88% with opiates by comparison 46.5% with 
medical cannabis.  
 Ware et al. (2015) found that patient’s physical function was greatly improved at their six 
and 12 month follow up appointments. “Average,” “low,” “current” and “highest” pain intensity 
was documented and the results revealed cannabis decreased the intensity in all trials compared 
to the placebo. Patients also reported a higher HRQoL score in other studies which relates to 
having a lower pain intensity score because there is less debilitation from their condition. 
Deshpande, Mailis-Gagnon, Zoheiry, and Lakha (2015) state there was clinically meaningful 
pain reduction in cannabis users compared to the placebo. For there to be clinical significance, a 
decrease in pain of two points on a numerical pain rating scale from 0 to 10 or a 30% 
improvement in the intensity of pain would qualify.  
 Nugent et al. (2017) conducted research relating to cannabis in treating chronic pain in 22 
randomized controlled trials (RTCs), two systemic reviews as well as eight further studies. The 
goal was to determine whether patients had a decrease in chronic pain following cannabis 
treatment. A numerical rating scale (NRS) as well as the visual analogue scale was used. Results 
showed a significant improvement in pain, a decrease of greater than 30% or two points on the 
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NRS scale as mentioned above. Nugent et al. also discussed findings found from National 
Academies of Sciences, Engineering, and Medicine. Findings were indicative of substantial 
benefit in chronic pain reduction in those who used cannabis. In those who used cannabinoid 
products, the AEs were of mild to moderate nature, contrary to some of the results found in other 
studies.  
 While there are numerous studies included within this research, one cannot make 
conclusions solely on the findings. This project was designed to present the research in a 
meaningful way and make inferences based on the studies. Furthermore, the research did not 
include in depth statistical analysis of each study’s statistics which would have provided further 
explanation of the results. Lastly, further research on this topic is needed in order to needs to 
further understand the benefits, safety and interactions that are associated with medical cannabis 
and cannabinoid products.  
Applicability to Clinical Practice/Policy 
 
 Due to the ever-changing field of medicine, as well as the different therapy modalities 
used for treatment of chronic pain, it is important to understand the different options available for 
use. Currently, there is a growing problem of overprescribing opiates as well as associated 
addiction and overdose due to these medications. With the legalization of cannabinoids, as well 
as the possible potential of its benefit for chronic pain therapy, this may be an option to help 
alleviate the current opiate epidemic.  
 Current research is showing there is benefit to medical cannabis as well as cannabinoids 
for certain chronic diseases and pain conditions such as fibromyalgia, neuropathy, multiple 
sclerosis, cystic fibrosis, migraines and gastrointestinal conditions to name a few. In some cases, 
there have been documented serious adverse events associated with the medication, however, 
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those situations are in the minority. Adverse events such as central nervous system depression, 
altered metal status and depressant effects were noted with cannabinoid use; of note, these events 
are also documented with the use opiate medications.  
 This therapy, while still controversial, is a possible positive alternative for pain 
management and like every other medication, clinicians should discuss the possible adverse 
events as well as the potential benefits associated with its use. Further research is needed to 
confirm if cannabinoid therapy is of greater benefit to opiate therapy, however, every individual 
is unique with different complaints and conditions, thus not every therapy will work for 
everyone. It does seem that there may be more benefit to using cannabinoids over opiate therapy 
due to the lower chances of addiction, similar or lessened side effects and possible decreased 
need for other pain medications. Opiate therapy on the other hand, tends to cause addiction and 
tolerance which leads to increasing the medication dosage, both of which are what cannabinoid 
therapy would help resolve. 
  While it appears, current research is in favor for medical cannabinoid treatment or as an 
adjunct therapy, results are not conclusive throughout the studies as well as there is not enough 
research to fully support its use at this time. Following more trials and studies, this form of 
therapy will be better understood, as well as if it will further aid in decreasing the current opiate 
need for chronic pain management. It is important for providers to begin to understand and take 
action against this growing opiate problem as well as consider possible alternatives to alleviate 
patient pain. Further research, as well as focused projects pertaining to specific chronic pain 
conditions, will be of benefit to better understand medical cannabis and cannabinoid products.  
 
 
CANNABINOID THERAPY IN CHRONIC PAIN MANAGEMENT  42 
References 
Aviram, J. & Samuelly-Leichtag, G. (2017). Efficacy of cannabis-based medicines for pain 
 management: a systematic review and meta-analysis of randomized controlled trials.  
 Pain Physician Journal, 20(6), E755-E596. Retrieved from  
 http://www.painphysicianjournal.com 
Boehnke, K., Litinas, E., & Clauw, D. (2016). Medical cannabis use is associated with decreased  
 opiate medication use in a retrospective cross-sectional survey of patients with chronic 
 pain. The Journal of Pain, 17(6), 739-744. http://doi.org/10.1016/j.jpain.2016.03.002 
Campbell, F., Tramer, M., Carroll, D., Reynolds, D., Moore, R., & McQuay, H. (2001). Are  
 cannabinoids as effective and safe treatment option in the management of pain? A  
 qualitative systematic review. British Medical Journal, 323(7303), 13-16.  
 http://doi.org/10.1136/bmj.323.7303.13 
Centers for Disease Control and Prevention (2017). Opioid overdose; understanding the  
 epidemic. Retrieved from https://www.cdc.gov 
Darvishi, N., Farhadi, M., Haghtalab, & Poorolajal., J. (2015). Alcohol-related risk of suicidal  
 
 ideation, suicide attempt, and complicated suicide: A meta-analysis. PLoS ONE, 10(5): 1- 
 
 14. http://doi.org/10.1371/journal.pone.0126870 
 
Deshpande, A., Mailis-Gagnon, A., Zoheiry, N., & Lakha, S. (2015). Efficacy and adverse  
 effects of medical marijuana for chronic noncancer pain. Systematic review of  
 randomized controlled trials. Canadian Family Physician, 61(8), E372-E381. Retrieved  
 from http://www.cfp.ca/content/61/8/e372 
Feingold, D., Goor-Aryeh, I., Bril, S., Delayahu, Y., & Lev-Ran, S. (2017). Problematic use of  
 prescription opioids and medical cannabis among patients suffering from chronic pain.  
CANNABINOID THERAPY IN CHRONIC PAIN MANAGEMENT  43 
 American Academy of Pain Medicine, 18(2), 294-306. http://doi.org/10.1093/pm/pnw134 
Goldenberg, M., Reid, M., IsHak, W., & Danovitch, I., (2017). The impact of cannabis and  
 cannabinoids for medical conditions on health-related quality of life: A systematic  
 review and meta-analysis. Drug and Alcohol Dependence, 174, 80-90. http://doi.org/ 
 10.1016/j.drugalcdep.2016.12.030 




Issa, M., Narang, S., Jamison, R., Michna, E., Edwards, R., Penetar, D., & Wasan, A. (2014).  
 The subjective psychoactive effects of oral dronabinol studies in a randomized, controlled  
 crossover clinical trial for pain. Clinical Journal of Pain, 30(6), 472-478. http://doi.org/ 
 10.1097/AJP.0000000000000022 
Lüscher, C. (2018). Drugs of abuse. In B.G. Katzung (Ed.), Basic & clinical pharmacology, 14e 
  
 (Chapter 32). New York, NY: McGraw-Hill. Available from AccessMedicine 
 
Lynch, M., & Campbell, F. (2011). Cannabinoids for treatment of chronic non-cancer pain; A 
 systematic review of randomized trials. British Journal of Clinical Pharmacology,  
 72(5), 735-744. http://doi.org/10.1111/j.1365-2125.2011.03970.x 
Martín-Sánchez, E., Furukawa, T., Taylor, J., & Martin, L. (2009). Systematic review and meta- 
 analysis of cannabis treatment for chronic pain. American Academy of Pain Medicine,  
 10(8), 1353-1368.  http://doi.org/10.1111/j.1526-4637.2009.00703.x  
National Conference of State Legislatures (2017). State medical marijuana laws. Retrieved  
 from https://www.ncsl.org 
National Institutes of Health (2017). Commonly abused drugs. National institute on drug abuse. 
 Retrieved from http://www.drugabuse.org 
CANNABINOID THERAPY IN CHRONIC PAIN MANAGEMENT  44 
Narang, S., Gibson, D., Wasan, A., Ross, E., Michna, E., Nedeljkovic, S., & Jamison R. (2008).  
 Efficacy of Dronabinol as an adjuvant treatment for chronic pain patients on opioid  
 therapy. The Journal of Pain, 9(3), 254-264. http://doi.org/10.1016/j.jpain.2007.10.018 
Nugent, S., Morasco, B., O’Neil, M., Freeman, M., Low, A., Kondo, K., . . . Kansagara, D.  
 (2017). The effects of cannabis among adults with chronic pain and an overview of  
 general harms. Annals of Internal Medicine, 167(5), 319-332. http://doi.org/10.7326/ 
 M17-0155 
Richter, L., Pugh, B., Smith, P., & Ball, S. (2016). The co-occurrence of nicotine and other 
 substance use and addiction among youth and adults in the United States: Implication for 
 research, practice, and policy. The American Journal of Drug and Alcohol Abuse, 43(2),  
 132-145. http://doi.org/10.1080/00952990.2016.1193511 
Ware, M., Wang, T., Shapiro, S., & Collet, J. (2015). Cannabis for the management of pain:  
 Assessment of safety study. The Journal of Pain, 16(12), 1233-1242. http://doi.org/10.10 
 16./j.jpain.2015.07.014 
Whiting, P., Wolff, R., Deshpande, S., Di Niso, M., Duffy, S., Hernandez, A., . . . Kleijnen, J.,  
  (2015). Cannabinoids for medical use: A systematic review and meta-analysis.  
 JAMA, 313(24) 2456-2473. https://doi.org/10.1001/jama.2015.6358 
